MASH & Liver Disease

2 articles in this topic.

Complete Guides

Semaglutide for Liver Fat: What the MASH Data Shows

Semaglutide resolved MASH in 63% of patients in the ESSENCE phase 3 trial and earned FDA approval. Review of 18 studies on GLP-1 therapy for liver fat.

20 min read|Mar 20, 2026

All Articles

MASH & Liver Disease

MASH: Peptide Solutions for Liver Disease

MASH (formerly NASH) affects 5-14% of adults globally. Semaglutide, tirzepatide, and survodutide show resolution rates of 44-74% in clinical trials.

13 min read|Mar 22, 2026